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Objective: The objective of this study was to determine the safety and efficacy of a 90-day regimen of rivaroxaban vs clopidogrel in addition to aspirin long term after lower extremity angioplasty.
Methods: In this single-center, open-label, phase 2, randomized trial, Rivaroxaban plus Aspirin Versus Standard Dual Antiplatelet Therapy Following Angioplasty for Lower Extremity Peripheral Arterial Disease (RIVAL-PAD), eligible patients with symptomatic lower extremity peripheral arterial disease, confirmed on imaging, were randomly assigned intraoperatively (1:1) to receive a 90-day regimen of rivaroxaban 2.5 mg twice daily vs clopidogrel 75 mg daily in addition to aspirin 81 mg long term in both treatment arms. The primary end point was a composite outcome of lesion-specific primary patency and freedom from target lesion revascularization or major amputation. Patency and ankle-brachial index (ABI) were determined on duplex ultrasound surveillance imaging at 1 month, 6 months, and 12 months by blinded observers. Data on adverse events were obtained in conjunction with a Data and Safety Monitoring Board. Major bleeding based on the International Society on Thrombosis and Haemostasis definition was the safety end point. This study is registered with ClinicalTrials.gov (NCT02260622).
Results: Between February 2015 and June 2016, there were 20 patients (44 target lesions) who were randomly assigned to either rivaroxaban plus aspirin (10 patients, 19 target lesions, 80% CLI) or clopidogrel plus aspirin (10 patients, 25 lesions, 50% CLI) at the time of their infrainguinal angioplasty procedure. There were no significant baseline differences with respect to ABIs (0.67 vs 0.61), lesion lengths (8.7 cm vs 9.9 cm), Bollinger scores (61.2 vs 77.7), runoff scores (9.0 vs 8.6), chronic total occlusions (21.1% vs 28.0%), and bailout stents (60% vs 70%) in the rivaroxaban plus aspirin vs clopidogrel plus aspirin arms. There were significant differences in postintervention ABIs (0.86 vs 0.65 [P ¼ .02] at 6 months; 0.91 vs 0.72 [P ¼ .04] at 12 months) and average target lesion peak systolic velocity (152.7 cm/s vs 240.9 cm/s [P ¼ .04] at 6 months), with a nonsignificant trend in the composite primary end point (primary patency, freedom from target lesion revascularization, and amputation; 84.2% vs 63.6% [P ¼ .14) at 6 months and 73.7% vs 59.1% [P ¼ .32] at 12 months) in favor of patients randomized to the rivaroxaban plus aspirin arm. No major or minor bleeding events were observed.
Conclusions: A postintervention regimen of rivaroxaban 2.5 mg twice daily for 90 days in combination with aspirin long term appears to be safe and has potential as an alternative to standard dual antiplatelet therapy in patients undergoing lower extremity interventions for symptomatic peripheral arterial disease. Results of this study support the conduct of a larger scale clinical trial.
Author Disclosures: P. Jetty: Off-label use of a drug, rivaroxaban; in this trial, approved by Health Canada, rivaroxaban 2.5 mg twice daily, in addition to aspirin, was administered to the treatment arm for 90 days following lower extremity angioplasty as an effort to improve patency and clinical outcomes; D. Kubelik: Nothing to disclose; A. Hill: Nothing to disclose; S. Nagpal: Nothing to disclose; T. Brandys: Nothing to disclose; G. Hajjar: Nothing to disclose; M. Lebouthelier: Nothing to disclose; E. Gandara: Nothing to disclose. Objective: The use of everolimus drug-eluting stents (eDESs) for endovascular bypass graft revision has not yet been reported. The objective of this study was to describe and to compare clinical outcomes of eDESs vs percutaneous cutting balloons (PCBs) vs angioplasty for the treatment of infrainguinal bypass graft stenoses.
Methods: An institutional analysis of patients with infrainguinal bypass graft stenosis treated by endovascular intervention (August 2010-December 2017) was conducted. Primary patency of the treated lesion and limb salvage were described overall and stratified by endovascular treatment modality using Kaplan-Meier curves and log-rank tests.
Results: During the 7-year study period, 42 patients with 76 infrainguinal bypass stenoses were treated by endovascular intervention (eDES, 14; PCB, 23; angioplasty, 39) . Mean age was 63 6 2 years; 52% were male, and 55% were black. The majority of patients were diabetic (60%) with a history of smoking (74%), and nearly all (83%) had two or more comorbidities. Half (49%) of bypasses being treated were femoropopliteal, followed by popliteal-distal (26%) and femorotibial (25%) configurations. The location of revision was the proximal anastomosis in 37%, midbypass in 26%, and distal anastomosis in 37%. There were no significant differences in baseline characteristics, bypass configuration, or revision location between treatment groups (P $ .19). Technical success for endovascular bypass intervention was 100%. Mean followup for all patients was 28 6 2 months. Based on Kaplan-Meier analysis, primary patency was significantly better for patients treated with eDESs (86%) compared with PCBs (61%) or angioplasty (44%; P ¼ .02; Fig) . Limb salvage was achieved in 95% of patients, including 93%, 91%, and 97% for eDESs, PCBs, and angioplasty, respectively (P ¼ .55).
Conclusions: This is the first study reporting the results of everolimuseluting stents for the treatment of infrainguinal bypass graft stenoses. Use of everolimus-eluting stents for endovascular bypass graft revision not only is feasible but may be more effective than other endovascular therapies. e67
